2022 Presenting Companies
Evaxion Biotech A/S
Evaxion-Biotech A/S (NASDAQ:EVAX) is a clinical-stage biotech company developing AI-powered immunotherapies for the treatment of various cancers, bacterial diseases and viral infections.
Our cancer portfolio is focussed on personalised neoantigen-targeting immunotherapies. We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.
EVX-01 has now entered phase 2b testing in metastatic melanoma following promising data from the phase 1/2a clinical trial with clear signs of clinical efficacy. We are completing a phase 1/2a trial with EVX-02 in adjuvant melanoma. Our third oncology program, EVX-03, is in preparation for clinical development within NSCLC.
Our infectious disease portfolio comprises EVX-B1 and EVX-B2.
EVX-B1 is a multi-component subunit vaccine for the prevention of S. aureus infections and is at IND-enabling stage. EVX-B2 is a vaccine against N. gonorrhoea in preclinical development.
We will soon be announcing EVX-V1, our first viral vaccine project.
All our pipeline projects are derived from our proprietary AI platforms: (i) PIONEER™, our immuno-oncology platform, (ii) EDEN™, our bacterial disease platform, and (iii) RAVEN™, our viral disease platform.